Sandy mom of six survives 15 years of blood cancer, helps other patients fight
Jenny Ahlstrom, 57, was diagnosed with , a form of blood cancer, in 2010. Following her diagnosis, she was presented with a lot of options for treatment.
'It's really hard to figure out, as a patient, what to do,' Ahlstrom told ABC4. 'I was looking for strategies where I could get treated and not have to be treated for a long time.'
A turning point in Ahlstrom's battle was receiving a known as CAR-T during clinical trials. The treatment, much like dialysis, included the removal of her blood cells, changing them in a lab, then infusing the cells back into her through an IV drip.
'Taking care of Jenny and taking care of her family… has just been remarkable,' Ahlstrom's doctor, Doug Sborov, said.
'Blessed and grateful': Teen survivor of West Valley murder-suicide graduates high school
According to Sborov, an Associate Professor at the University of Utah's Huntsman Cancer Institute, multiple myeloma is generally considered to be 'incurable.' However, with new research and medications, like CAR-T, physicians can drastically lengthen patients' lives and improve their quality of life.
'Here I am, three years later, completely disease free,' Ahlstrom said.
'She's provided patients an incredible opportunity to be educated. She's provided researchers, like myself, an incredible opportunity to engage with patients and really fundamentally change how we're approaching how we take care of these folks,' Sborov told ABC4.
Jenny Ahlstrom raises awareness about available resources for blood cancer patients. (Courtesy Stacey Isaacs)
Now, Ahlstrom leads a nonprofit called that raises awareness and increases access to vital data for researchers.
'If we're going to make advances in healthcare, we need to leapfrog forward in innovation,' Ahlstrom said.
Ahlstrom says there are about 35,000 new diagnoses of myeloma every year and 150,000 living patients with myeloma.
'It's really amazing to bring these new types of therapy to these patients,' Ahlstrom said. 'It's available and it's here.'
Trump to pardon reality TV stars Todd and Julie Chrisley
Sandy mom of six survives 15 years of blood cancer, helps other patients fight
Orem woman allegedly blocks driver, causing 'significant congestion' during road rage incident
RFK Jr. ends COVID shot recommendation for healthy kids, pregnant women
President Trump appears to lose patience with Putin
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete response at six months with CD19 CAR-NK in combination with rituximab and a third WM patient has been enrolled in the study First study to demonstrate the potential for complete responses with a chemotherapy-free immunotherapy in late-stage WM patients validating the power of NK cells CULVER CITY, Calif., August 13, 2025--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. QUILT-106 (NCT06334991) is a first-in-human trial evaluating the safety and preliminary efficacy of CD19 CAR-NK cell therapy alone and in combination with rituximab in patients with relapsed or refractory (R/R) CD19⁺CD20⁺ B-cell NHL. The disease remains challenging to treat, and WM is considered incurable with existing treatment options, making novel immunotherapies an important avenue of exploration for potential effective treatments. In the first two evaluable patients with WM who were heavily pretreated, an entirely chemotherapy-free, immunotherapy regimen induced encouraging responses. Both patients tolerated the regimen with no significant toxicities. Notably, all infusions (including CAR-NK cells and cytokines) were administered in an outpatient setting. One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date. The open-label study sponsored by ImmunityBio and led by Dr. Glenda Gray, former President and CEO of the South African Medical Research Council (SAMRC) and current Chair of the Global Antibiotic Research and Development Partnership (GARDP), has enrolled 13 patients with NHL at three sites in South Africa. Of the patients enrolled so far, three have WM. Eligible study participants express CD19 and CD20, with active disease after ≥2 chemotherapy-based lines of treatment. All patients receive a lead-in cycle of CD19 CAR-NK cell monotherapy, followed by a 1-week safety observation pause, then a second cycle combining CD19 CAR-NK with rituximab. Key endpoints include safety/tolerability and objective response rate (ORR) by standard criteria. "The preliminary findings we have submitted for presentation at the American Society of Hematology annual meeting provides the first evidence that novel immunotherapy combinations without chemotherapy lymphodepletion can provide deep and durable remissions in WM even after multiple prior treatments," said Dr. Jackie Thomson, Wits University Donald Gordan Medical Center, Johannesburg, South Africa and the lead author of the paper. "Recruitment in this rare subset of lymphoma is ongoing to confirm these findings and to establish this chemo-free strategy as a viable treatment option for relapsed WM." ImmunityBio's CD19 CAR-NK Therapy CD19 CAR-NK is a targeted high-affinity natural killer cell therapy – an off-the-shelf, allogeneic NK cell line engineered to express a CD19-specific chimeric antigen receptor (CAR) and a high-affinity CD16 (FcγRIIIa 158V) receptor. This design enables dual anti-tumor mechanisms: direct CAR-mediated cytotoxicity and augmented antibody-dependent cellular cytotoxicity when paired with anti-CD20 monoclonal antibody rituximab. Combining CD19 CAR-NK cells with rituximab could thereby target CD19⁺/CD20⁺ lymphoma cells to enhance tumor cell killing. About ImmunityBio ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding potential implications to be drawn from preliminary clinical study results, clinical trial enrollment, timing, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's CancerBioShield™ platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that have the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from the clinical trial described herein, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio's ability to retain and hire key personnel, (viii) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on August 5, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. View source version on Contacts InvestorsHemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 MediaSarah Singleton ImmunityBio, Inc. +1 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 days ago
- The Hill
Semaglutides may shrink muscle size, strength: Study
New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, raising questions about muscle strength and organ size after significant weight loss. University of Utah scientists studied semaglutide, the active ingredient in weight loss medications, in mice. In the study, published in the journal Cell Metabolism, researchers revealed 'unexpected effects,' highlighting that lean mass, or body weight that isn't fat, dropped about 10 percent. Most of the loss came from non-muscle tissues, particularly the liver, which shrank by nearly half. Some skeletal muscles lost around 6 percent of their size, while others remained unchanged. Despite relatively small changes in muscle size, certain muscles became weaker. Researchers said this could be especially concerning for adults over 60, who already face higher risks of muscle loss and reduced mobility. 'The loss of physical function is a strong predictor of not just quality of life but longevity,' said Katsu Funai, the senior author on the study. The findings challenge the assumption that lean mass loss comes mainly from skeletal muscle. Instead, they point to changes in metabolically active organs, such as the liver, which can shrink during healthy weight loss without harming function. 'It's unlikely that the observed lean mass loss represents a serious adverse effect,' said Takuya Karasawa, co-first author on the study. Still, scientists emphasize that further human studies are necessary to determine whether similar effects occur in humans and whether they pose health risks. 'There remains a significant need for validation in humans, especially concerning muscle strength,' Karasawa said. They also suggest that future clinical trials should track not only lean mass but also muscle strength and physical function, especially as more weight loss drugs enter the market. 'There are many additional weight loss drugs that are in clinical trials and coming out in the next three to five years,' Funai said. 'But with all those clinical trials, if they're interested in measuring lean mass loss, they need to consider physical function.'
Vogue
2 days ago
- Vogue
How to Bring the Broderie Anglaise Decor Trend Home
Call it nostalgia or a rebellion against the clean functionality of minimalism, but romantic, decorative textiles are having a moment. We're indulging in all the trimmings: think, bed linens edged with ruffles; eyelet or broderie anglaise trims; and napkins, placemats, and tablecloths adorned with intricate lace and embroidery. If you think you've been seeing more and more of these dainty styles sneaking onto your social feeds and saturating shops, it's not in your head. Sales of these ultra-feminine accents have doubled at the homeware site Abask in the last year, according to a rep for the brand, with the biggest growth seen in white-on-white pieces, heritage-inspired detailing, and—yes—ruffles. Earlier this summer, Danish textile brand Tekla launched an entire bedding collection spotlighting broderie anglaise. Could our renewed love of delicate home textiles reflect a wider sartorial fascination with lace-trimmed skirts, doily-like crochet headwear, and dresses that wouldn't look out of place in the Victorian era–or is something else at play? 'I think people are craving a gentler aesthetic,' says Laila Gohar, artist and co-founder of Gohar World, whose playful embroidered and lace-appliquéd table linens were inspired by her childhood in Egypt. 'Every design movement, whether in fashion or interiors, is a reaction to what came before it. A few years ago, it was all about the clean, sleek lines of Scandinavian minimalism. Now, there's a yearning for things that feel like precious, handmade heirlooms. Lace fits into that nicely.'
